Log in

NASDAQ:CODXCo-Diagnostics Stock Price, Forecast & News

$18.55
+0.53 (+2.94 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.58
Now: $18.55
$18.80
50-Day Range
$7.46
MA: $13.40
$23.42
52-Week Range
$0.69
Now: $18.55
$29.72
Volume2.74 million shs
Average Volume11.00 million shs
Market Capitalization$509.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.78 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone801-438-1036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$0.10 per share

Profitability

Net Income$-6,200,000.00
Net Margins-334.58%

Miscellaneous

Employees22
Market Cap$509.38 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

How has Co-Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CODX stock has increased by 40.6% and is now trading at $18.55. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Co-Diagnostics.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Co-Diagnostics.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics Inc (NASDAQ:CODX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The business earned $1.55 million during the quarter, compared to analyst estimates of $1.10 million. Co-Diagnostics had a negative net margin of 334.58% and a negative return on equity of 81.15%. View Co-Diagnostics' earnings history.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics updated its fourth quarter earnings guidance on Tuesday, March, 31st. The company provided earnings per share guidance of ($0.36) for the period, compared to the Thomson Reuters consensus estimate of ($0.09). The company issued revenue guidance of $214.97 million, compared to the consensus revenue estimate of $0.10 million.

What price target have analysts set for CODX?

2 Wall Street analysts have issued twelve-month target prices for Co-Diagnostics' shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate Co-Diagnostics' stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 83.8%. View analysts' price targets for Co-Diagnostics.

Has Co-Diagnostics been receiving favorable news coverage?

Press coverage about CODX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Co-Diagnostics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutCo-Diagnostics.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Moderna (MRNA), Advanced Micro Devices (AMD), Vaxart (VXRT), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU) and Alibaba Group (BABA).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)
  • Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)
  • Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (1.34%), Geode Capital Management LLC (0.44%), Harvest Investment Services LLC (0.24%), IFG Advisory LLC (0.22%), Wealth Architects LLC (0.15%) and HighTower Advisors LLC (0.12%). View institutional ownership trends for Co-Diagnostics.

Which institutional investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC. View insider buying and selling activity for Co-Diagnostics.

Which institutional investors are buying Co-Diagnostics stock?

CODX stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Harvest Investment Services LLC, IFG Advisory LLC, Wealth Architects LLC, Engineers Gate Manager LP, Paloma Partners Management Co, and Strategic Wealth Management Group LLC. View insider buying and selling activity for Co-Diagnostics.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $18.55.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $509.38 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 22 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.